Treatment of Malignant Ascites

Keywords

Law, Unit (ring theory), Aeronautics, Engineering, Computer security

References

• Matrix Metalloproteinase Inhibitors: Applications in OncologyDesmond Yip, Athar Ahmad, Christos S. Karapetis — 2004
• A new approach to the management of malignant ascites; a permanently implanted abdominal drain.M. Belfort, P J Stevens, K DeHaek — 1990
• The past, the present and future of the OK-432 therapy for patients with malignant effusions.M Katano, Takahiro Morisaki — 1998
• Treatment of malignant peritoneal effusion in digestive and ovarian cancerFrançois Noël Gilly, Pierre Y. Carry, ALain Bracket — 1992
• Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics.Paul J. Pockros, Karl Esrason, Cuong Nguyen — 1992
• Malignant ascites: demographics, therapeutic efficacy and predictors of survival.John R. Mackey, Peter Venner — 1996
• Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy.Brian W. Loggie, Marcos V. Perini, Ronald A. Fleming — 1997
• A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity.Gerrit Los, O. A. G. Smals, Marianne J.H. van Vugt — 1992
• Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites.G. J. Beattie, J F Smyth — 1998
• Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.Jin Luo, Masashi Toyoda, Masabumi Shibuya — 1998
• The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.Jennifer A. Low, Michael D. Johnson, Elisabeth A. Bone — 1996
• Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer.Richard L. Schilsky, Kyung Eob Choi, John T. Grayhack — 1990
• A randomized trial of paracentesis plus intraperitoneal tumor necrosis factor-alpha versus paracentesis alone in patients with symptomatic ascites from recurrent ovarian carcinoma.Holger W. Hirte, Daniel Miller, Katia Tonkin — 1997
• Human leukocyte interferon therapy for advanced ovarian carcinoma.Nina Einhorn, Kari Cantell, Stefan Einhorn — 1982
• The current and future management of malignant ascites.Ed Smith, Gordon C. Jayson — 2003
• Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesotheliomaMaurie Markman, David P. Kelsen — 2005
• Intraperitoneal recombinant interferon‐alpha 2b for recurrent malignant ascites due to ovarian cancerW. R. Bezwoda, Leslie Seymour, Roger Dansey — 1989
• Malignant ascites: past, present, and future.Rony A. Adam, Yehuda G. Adam — 2004
• Malignant ascites: a 2-year review from a teaching hospital.Simon L. Parsons, Martin W. Lang, R. Steele — 1996
• Comparison of percutaneous management techniques for recurrent malignant ascites.Stefanie M. Rosenberg, Angi Courtney, Albert A. Nemcek — 2004

Cited by

• Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (Hipec) for Palliative treatment of Malignant Ascites from Gastrointestinal Stromal TumoursEvan Ong, Conrad Diven, Andrew Abrams — 2012
• 婦人科癌による難治性癌性腹水に対して腹水濾過濃縮再静注法 （cell-free and concentrated ascites reinfusion therapy ; CART） を施行した7症例松尾 愛理, 河原 俊介, 泉 有希子 — 2014
• The anthelmintic drug mebendazole inhibits growth, migration and invasion in gastric cancer cell model.Laine Celestino Pinto, Bruno Moreira Soares, João de Jesus Viana Pinheiro — 2015
• The effect of abdominal massage in reducing malignant ascites symptoms.Tsae‐Jyy Wang, Hung‐Ming Wang, Tsai‐Sheng Yang — 2015
• Tacrolimus Disposition in the Ascitic Fluid of a Bone Marrow Transplant PatientR. Ibrahim, Muneer H. Abidi, Zaid Al‐Kadhimi — 2010
• [Permanent tunneled drainage for malignant ascites: initial experience with the PleurX® catheter].R. Saiz-Mendiguren, M. Gómez-Ayechu, J.J. Noguera — 2010
• [Permanent tunneled drainage for malignant ascites: initial experience with the PleurX® catheter].R. Saiz-Mendiguren, M. Gómez-Ayechu, J.J. Noguera — 2010
• Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS studyKlaus Pietzner, Ignace Vergote, Armando Santoro — 2014
• TEMA 14-2014: MANEJO DE LA ASCITIS MALIGNA NO REFRACTARIAAndrea M. Medina Méndez, David F. Ávalos Chacón — 2014
• CatumaxomabJames E. Frampton — 2012
• A survey of treatment approaches of malignant ascites in Germany and AustriaC. Jehn, S. Küpferling, Gülten Oskay-Özcelik — 2015
• Oxidative dna damage of lymphocytes in peripheral blood and ascites in cancer patients.J. Wang, Shuning Xing, Songxi Guo — 2012
• 84-year-old man with respiratory distress and abdominal distention.Deirdre R. Pachman, Thomas B. Morrison, Jason H. Szostek — 2011
• Multi-detector CT in peritoneal carcinomatosis: diagnostic role of thin slices and multiplanar reconstructionsTobias Franiel, Gerd Diederichs, F. Engelken — 2008
• Management of malignancy-related ascites.Anne Marie C. Flaherty — 2015
• Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites.Hongmei Wei, Shukui Qin, Xiaojin Yin — 2015
• Estudio descriptivo sobre el uso de catéteres peritoneales en el manejo de la ascitis malignaPilar Sales Moreno, Agnès Calsina-Berna, Montserrat López Postigo — 2012
• Management of symptomatic ascites and post-operative lymphocysts with an easy-to-use, patient-controlled, vascular catheter.Maciej Stukan, Krzysztof Leśniewski-Kmak, Magdalena Wróblewska — 2015
• The Role of Laparoscopy in Peritoneal Surface Malignancies Selected for Hyperthermic Intraperitoneal Chemotherapy (HIPEC)Antonio Sommariva, Vittorina Zagonel, Carlo Riccardo Rossi — 2012
• Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian CancerDiana Moughon, Huanhuan He, Shiruyeh Schokrpur — 2015

Related papers

• True Battlefield VisibilityNorman R. Denny — 2004
• Battle Command: Toppling the Tower of BabelStuart A. Whitehead — 2005
• Who's in Charge? Commander, Air Force Forces or Air Force Commander?Brian W McLean — 2013
• Radical C(2) Doctrine and CP DesingJack Burkett — 2002
• The Real Military RevolutionThomas K. Adams — 2000
• The Evolution of Mission Command 4 in U.S. Army Doctrine, 1905 to the PresentC. J. Ancker — 2013
• Achieving Sensor-to-Shooter SynergyFrank J. Caravella — 1998
• Strength in Numbers the Remarkable Potential of (Really) Small CombatantsJimmy Drennan — 2014